Abstract
Background: The International Parkinson and Movement Disorder Society-endorsed Progressive Supranuclear Palsy Study Group published clinical diagnostic criteria for progressive supranuclear palsy in 2017, aiming to optimize early, sensitive and specific diagnosis. Objective: To assist physicians in the application of these criteria, we developed a video-based tutorial in which all core clinical features and clinical clues are depicted and explained. Methods: Patients provided written informed consent to the publication of their videos. High-quality videos along with essential descriptions were collected by the study group members. Most educational videos were selected in a structured consensus process. Results: We provide 68 videos of all core clinical features and clinical clues defined by the diagnostic criteria, along with instructive descriptions of the depicted patients, examination techniques and clinical findings. Conclusions: This comprehensive video-based tutorial will support physicians in the application of the diagnostic criteria of progressive supranuclear palsy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 200-203 |
| Number of pages | 4 |
| Journal | Parkinsonism and Related Disorders |
| Volume | 78 |
| DOIs | |
| State | Published - Sep 2020 |
Keywords
- Clinical diagnostic criteria
- Phenotype
- Progressive supranuclear palsy
- Video tutorial
ASJC Scopus subject areas
- Neurology
- Geriatrics and Gerontology
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Parkinsonism and Related Disorders, Vol. 78, 09.2020, p. 200-203.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy
AU - for the Movement Disorder Society-Endorsed PSP Study Group
AU - Iankova, Vassilena
AU - Respondek, Gesine
AU - Saranza, Gerard
AU - Painous, Cèlia
AU - Cámara, Ana
AU - Compta, Yaroslau
AU - Aiba, Ikuko
AU - Balint, Bettina
AU - Giagkou, Nikolaos
AU - Josephs, Keith A.
AU - Otsuki, Mika
AU - Golbe, Lawrence I.
AU - Bhatia, Kailash P.
AU - Stamelou, Maria
AU - Lang, Anthony E.
AU - Höglinger, Günter U.
N1 - Funding Information: Kailash P Bhatia holds research grants from NIHR RfPB , MRC Wellcome Strategic grant (Ref. no.: WT089698 ) and PD UK (Ref. no.: G-1009 ), and has received honoraria/financial support to speak/attend meetings from GSK , Boehringer-Ingelheim, Ipsen , Merz, Sun Pharma , Allergan , Teva Lundbeck and Orion pharmaceutical companies . KB receives royalties from Oxford University press and a stipend for MDCP editorship. Funding Information: The project was supported by the German Center for Neurodegenerative Diseases e.V. (DZNE) , German PSP Gesellschaft , and the International Parkinson & Movement Disorder Society . Funding Information: Keith A. Josephs is funded by the National Institute of Health .Mika Otsuki has nothing to disclose. Funding Information: Ana Cámara has received funding or support from Abbvie and Medtronic as well as from the H2020 lPI043760 grant. She has a competitive PERIS grant from the Department of Health of the Generalitat de Catalunya ( SLT008/18/00191 ). Funding Information: Yaroslau Compta has served as a consultant for Abbvie and Zambon, and has received honoraria for scientific presentations from Abbvie, Alter, Bial, Medtronic, Merz, Teva, UCB, and Zambon. He is currently an associate editor of Parkinsonism & Related Disorders (Elsevier). He has competitive grants from Instituto de Salud Carlos III (ISCIII) / Spanish Ministry of Health ( PI17/00096 ) and the European Commission H2020 program ( lPI043760 ). YC’s center receives support from the CERCA program of Generalitat de Catalunya and the Maria de Maeztu program of the Spanish Ministry of Education , and is part of the European Reference Network for Rare Neurological Diseases (ERN-RND) . Funding Information: Ikuko Aiba serves as a consultant for Abbvie and Biogen.Bettina Balint is supported by the Robert Bosch Foundation .Nikolaos Giagkou has nothing to disclose. Funding Information: Vassilena Iankova has nothing to disclose. Gesine Respondek has nothing to disclose. Gerard Saranza has nothing to disclose. Cèlia Painous has received support from Boston and has a competitive Río Hortega predoctoral grant from the Spanish Ministry of Health . Funding Information: Vassilena Iankova has nothing to disclose. Gesine Respondek has nothing to disclose. Gerard Saranza has nothing to disclose. Cèlia Painous has received support from Boston and has a competitive Río Hortega predoctoral grant from the Spanish Ministry of Health.Ana Cámara has received funding or support from Abbvie and Medtronic as well as from the H2020 lPI043760 grant. She has a competitive PERIS grant from the Department of Health of the Generalitat de Catalunya (SLT008/18/00191).Yaroslau Compta has served as a consultant for Abbvie and Zambon, and has received honoraria for scientific presentations from Abbvie, Alter, Bial, Medtronic, Merz, Teva, UCB, and Zambon. He is currently an associate editor of Parkinsonism & Related Disorders (Elsevier). He has competitive grants from Instituto de Salud Carlos III (ISCIII) / Spanish Ministry of Health (PI17/00096) and the European Commission H2020 program (lPI043760). YC's center receives support from the CERCA program of Generalitat de Catalunya and the Maria de Maeztu program of the Spanish Ministry of Education, and is part of the European Reference Network for Rare Neurological Diseases (ERN-RND).Ikuko Aiba serves as a consultant for Abbvie and Biogen.Bettina Balint is supported by the Robert Bosch Foundation.Nikolaos Giagkou has nothing to disclose.Keith A. Josephs is funded by the National Institute of Health.Mika Otsuki has nothing to disclose.Lawrence I. Golbe receives research support from Biogen and AbbVie and serves as a consultant for CurePSP, Biogen, AbbVie, UCB, Asceneuron, GLG, Piramal, Pinteon, NeuroTrax and Novartis.Kailash P Bhatia holds research grants from NIHR RfPB, MRC Wellcome Strategic grant (Ref. no.: WT089698) and PD UK (Ref. no.: G-1009), and has received honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck and Orion pharmaceutical companies. KB receives royalties from Oxford University press and a stipend for MDCP editorship.Maria Stamelou serves as assistant editor in Movement Disorders Journal, has received travel and speaker honoraria from Biogen, UCB, Abbvie and Specifar, MDS and EAN, royalties from Oxford and Cambridge University Press, has served in as advisory board to Biogen and Specifar and receives research support from PPMI.Günter U. Höglinger has ongoing research collaborations with Orion, Prothena; serves as a consultant for Abbvie, Alzprotect, Asceneuron, Biogen, Biohaven, Novartis, Sanofi, UCB; received honoraria for scientific presentations from Abbvie, Biogen, Roche, Teva, UCB, Zambon, has received research support from CurePSP, the German Academic Exchange Service (DAAD), German Parkinson's Disease Foundation (DPG), German PSP Association (PSP Gesellschaft), German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF), International Parkinson's Fonds (IPF); has received institutional support from the German Center for Neurodegenerative Diseases (DZNE).The project was supported by the German Center for Neurodegenerative Diseases e.V. (DZNE), German PSP Gesellschaft, and the International Parkinson & Movement Disorder Society.The authors would like to thank Naomi Matsuda, PT, Yoriko Omote, PT, Hiroshi Nishimura, OT, Kousuke Kobayashi, ST, of the Department of Rehabilitation, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan and Rina Hashimoto, MD, PhD, Satoko Sakakibara, MD of the Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan, for their support. Publisher Copyright: © 2020
PY - 2020/9
Y1 - 2020/9
N2 - Background: The International Parkinson and Movement Disorder Society-endorsed Progressive Supranuclear Palsy Study Group published clinical diagnostic criteria for progressive supranuclear palsy in 2017, aiming to optimize early, sensitive and specific diagnosis. Objective: To assist physicians in the application of these criteria, we developed a video-based tutorial in which all core clinical features and clinical clues are depicted and explained. Methods: Patients provided written informed consent to the publication of their videos. High-quality videos along with essential descriptions were collected by the study group members. Most educational videos were selected in a structured consensus process. Results: We provide 68 videos of all core clinical features and clinical clues defined by the diagnostic criteria, along with instructive descriptions of the depicted patients, examination techniques and clinical findings. Conclusions: This comprehensive video-based tutorial will support physicians in the application of the diagnostic criteria of progressive supranuclear palsy.
AB - Background: The International Parkinson and Movement Disorder Society-endorsed Progressive Supranuclear Palsy Study Group published clinical diagnostic criteria for progressive supranuclear palsy in 2017, aiming to optimize early, sensitive and specific diagnosis. Objective: To assist physicians in the application of these criteria, we developed a video-based tutorial in which all core clinical features and clinical clues are depicted and explained. Methods: Patients provided written informed consent to the publication of their videos. High-quality videos along with essential descriptions were collected by the study group members. Most educational videos were selected in a structured consensus process. Results: We provide 68 videos of all core clinical features and clinical clues defined by the diagnostic criteria, along with instructive descriptions of the depicted patients, examination techniques and clinical findings. Conclusions: This comprehensive video-based tutorial will support physicians in the application of the diagnostic criteria of progressive supranuclear palsy.
KW - Clinical diagnostic criteria
KW - Phenotype
KW - Progressive supranuclear palsy
KW - Video tutorial
UR - http://www.scopus.com/inward/record.url?scp=85090302755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090302755&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2020.06.030
DO - 10.1016/j.parkreldis.2020.06.030
M3 - Article
C2 - 32988736
AN - SCOPUS:85090302755
SN - 1353-8020
VL - 78
SP - 200
EP - 203
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -